4//SEC Filing
O'Neil Thomas P. 4
Accession 0001567619-20-012820
CIK 0001692830other
Filed
Jul 1, 8:00 PM ET
Accepted
Jul 2, 4:15 PM ET
Size
16.1 KB
Accession
0001567619-20-012820
Insider Transaction Report
Form 4
O'Neil Thomas P.
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock, $0.0001 par value
2020-07-01$4.56/sh+300$1,368→ 300 total - Sale
Common Stock, $0.0001 par value
2020-07-01$26.70/sh−394$10,520→ 0 total - Sale
Common Stock, $0.0001 par value
2020-07-01$25.63/sh−300$7,690→ 0 total - Exercise/Conversion
Common Stock, $0.0001 par value
2020-07-01$4.56/sh+394$1,797→ 394 total - Exercise/Conversion
Common Stock, $0.0001 par value
2020-07-01$4.56/sh+306$1,395→ 306 total - Sale
Common Stock, $0.0001 par value
2020-07-01$27.59/sh−306$8,444→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-07-01−1,000→ 67,340 totalExercise: $4.56Exp: 2029-05-16→ Common Stock (1,000 underlying)
Footnotes (5)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- [F2]The transaction was executed in multiple trades in prices ranging from $25.35 to $26.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]The transaction was executed in multiple trades in prices ranging from $26.40 to $27.00, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]The transaction was executed in multiple trades in prices ranging from $27.50 to $27.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F5]The option vest and become exercisable in successive, equal monthly installments over four years measured from May 15, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Documents
Issuer
Satsuma Pharmaceuticals, Inc.
CIK 0001692830
Entity typeother
Related Parties
1- filerCIK 0001640645
Filing Metadata
- Form type
- 4
- Filed
- Jul 1, 8:00 PM ET
- Accepted
- Jul 2, 4:15 PM ET
- Size
- 16.1 KB